Black Diamond Therapeutics (BDTX) EPS (Weighted Average and Diluted): 2020-2021
Historic EPS (Weighted Average and Diluted) for Black Diamond Therapeutics (BDTX) over the last 2 years, with Dec 2021 value amounting to -$0.71.
- Black Diamond Therapeutics' EPS (Weighted Average and Diluted) fell 12.70% to -$0.71 in Q4 2021 from the same period last year, while for Dec 2021 it was -$3.15, marking a year-over-year decrease of 44.27%. This contributed to the annual value of -$3.47 for FY2021, which is 69.27% down from last year.
- Per Black Diamond Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.71 for Q4 2021, which was up 26.80% from -$0.97 recorded in Q3 2021.
- In the past 5 years, Black Diamond Therapeutics' EPS (Weighted Average and Diluted) registered a high of -$0.50 during Q3 2020, and its lowest value of -$0.97 during Q3 2021.
- In the last 2 years, Black Diamond Therapeutics' EPS (Weighted Average and Diluted) had a median value of -$0.63 in 2020 and averaged -$0.67.
- Data for Black Diamond Therapeutics' EPS (Weighted Average and Diluted) shows a maximum YoY slumped of 94.00% (in 2021) over the last 5 years.
- Black Diamond Therapeutics' EPS (Weighted Average and Diluted) (Quarterly) stood at -$0.63 in 2020, then fell by 12.70% to -$0.71 in 2021.
- Its EPS (Weighted Average and Diluted) was -$0.71 in Q4 2021, compared to -$0.97 in Q3 2021 and -$0.84 in Q2 2021.